Symphera, a Munich-based medical device startup, has successfully closed a €2.4 million seed financing round. The round was led by High-Tech Gründerfonds (HTGF) and saw participation from Bayern Kapital, CARMA FUND, UnternehmerTUM Funding for Innovators, Stern Stewart Ventures, as well as renowned international partners such as IRCAD from Strasbourg and expert business angels from the medical field.

Symphera develops advanced surgical systems for laparoscopic procedures that automate tool-switching. The company’s technology makes manual instrument changes obsolete. With the push of a button, surgeons can seamlessly switch between instruments, much like using a multipen, allowing them to maintain full focus throughout the whole procedure. The goal is to simplify surgical workflows, reduce the operating time and improve post-operative outcomes for patients.

The company’s mission aligns with current trends in healthcare that aim to increase operating room efficiency and provide surgeons with better working environments. With its technology, Symphera is well-positioned to meet the demand for more efficient surgical procedures and has gained support from leading experts and institutions specializing in minimally invasive surgery.

Dr. Jan Engels, Investment Manager at HTGF, said: “With its surgical tool, Symphera addresses the entire spectrum of laparoscopy, from improving the standard workflow to robot-assisted applications, making Symphera a strong venture case in a highly interesting field.”

Monika Steger, Managing Director at Bayern Kapital, added: “With its all-in-one instrument, the Symphera team has developed a way to make shorter operations possible. Symphera’s existing prototype has convinced us and makes Symphera an exciting investment case for us in the medtech sector.”

With the newly secured funding, Symphera plans to advance the development of its product, conduct initial pre-clinical tests to initiate the preparation for the certification process. These steps are critical in bringing their technology closer to market, with the ultimate goal of transforming laparoscopic surgery and improving patient care.

Christian Leikert, Managing Partner at CARMA FUND, commented: “We are intrigued by the company’s founders and its potential to revolutionize laparoscopic surgery with a straight-forward technology. Its potential future application in robotic and robotic-assisted surgery provides significant further upside potential to Symphera.”

– Advertisement –